Samuel A Wells
Affiliation: National Institutes of Health
- Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an updateSamuel A Wells
Cancer Genetics Branch, National Cancer Institute, National Institutes of Health, Building 37, Room 10106A, 37 Convent Drive, Bethesda, Maryland 20814, USA
J Clin Endocrinol Metab 98:3149-64. 2013..In this manuscript, we summarize how recent discoveries have enhanced our understanding of the molecular basis of these diseases and led to improvements in the diagnosis and management of affected patients...
- Targeting the RET pathway in thyroid cancerSamuel A Wells
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:7119-23. 2009..Also, recently developed molecular therapeutics that target the RET pathway have shown activity in clinical trials of patients with advanced MTC, a disease for which there has been no effective therapy...
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialSamuel A Wells
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N 240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Clin Oncol 30:134-41. 2012....
- Revised American Thyroid Association guidelines for the management of medullary thyroid carcinomaSamuel A Wells
1Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Thyroid 25:567-610. 2015..The American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association...
- Update: the status of clinical trials with kinase inhibitors in thyroid cancerSamuel A Wells
Cancer Genetics Branch S A W, National Cancer Institute, Bethesda, Maryland 20892 and Dipartimento di Medicina Molecolare e Biotecnologie Mediche M S, Universita di Napoli Federico II, 80131 Napoli, Italy
J Clin Endocrinol Metab 99:1543-55. 2014....
- Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastasesAnna Tamburrino
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 18:3532-40. 2012..Understanding the molecular pathogenesis of medullary thyroid carcinoma (MTC) is prerequisite to the design of targeted therapies for patients with advanced disease...
- Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2Jeffrey F Moley
Department of Surgery, Washington University School of Medicine, St Louis, MO Department of Surgery, UT Southwestern, Dallas, TX Department of Surgery, Scott and White Medical Center, Temple, TX Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
Ann Surg 262:641-6. 2015..Management of the parathyroids during thyroidectomy is controversial. Some experts advocate total parathyroidectomy with autotransplantation, whereas others recommend preserving the parathyroids in situ...
- The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutationsChan Kwon Jung
Department of Pathology C K J, Y E N, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 Department of Hospital Pathology C K J, The Catholic University of Korea, Seoul 137 701, Republic of Korea and Radiation Epidemiology and Biostatistics Branches J H L, A v B, M P L, A J S, Division of Cancer Epidemiology and Genetics and Cancer Genetics Branch S A W, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
J Clin Endocrinol Metab 99:E276-85. 2014..Thyroid cancer incidence rates in the United States and globally have increased steadily over the last 40 years, primarily due to a tripling of the incidence of papillary thyroid carcinoma (PTC)...